FHI 360 receives award to operate HIV Prevention Trials Network’s Leadership and Operations Center
DURHAM, NC — FHI 360, a global human development organization with a decades-long legacy in HIV prevention research, has received a seven-year award to continue to serve as the Leadership and Operations Center (LOC) for the HIV Prevention Trials Network (HPTN).
The award is part of a multimillion-dollar grant to HPTN through a collaborative agreement from the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) to further the Network’s efforts in identifying interventions and strategies that will reduce HIV transmission in the most severely impacted populations. This research grant is awarded to FHI 360 as the LOC and supported by NIAID and NIH under Award Number UM1AI068619.
“We are grateful to the NIH for its continued support,” said Dr. Timothy Mastro, Group Director of Global Health, Population and Nutrition at FHI 360. “FHI 360 is thrilled to continue to be part of HPTN and to advance HIV prevention research domestically and globally.”
HPTN is a worldwide, collaborative, clinical trials network that brings together investigators, ethicists, communities and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention intervention strategies in populations and geographical regions that bear a disproportionate burden of infection.
Based at FHI 360’s headquarters in Durham, NC, the LOC is responsible for the Network’s scientific management, which includes review of research concepts, protocol development and implementation in the field, network budget and governance, communications, and management of HPTN committees.
“We are delighted to continue to be part of HPTN in its third iteration,” said Nirupama Sista, PhD, HPTN Director at FHI 360. “The LOC plays a critical role in all aspects of HPTN, generating scientific ideas, developing study protocols, and managing the budget and governance of the network.”
HPTN’s other central resources include the Laboratory Center, located at the Johns Hopkins University in Baltimore, MD, and the Statistical and Data Management Center, based at the Statistical Center for HIV/AIDS Research and Prevention at the Fred Hutchinson Cancer Research Center in Seattle, WA. HPTN encompasses more than 25 research sites in 15 countries and more than 50 ongoing or completed clinical trials.
FHI 360 experts have supported a number of HPTN trials in the United States and other regions of the world. Among HPTN’s research accomplishments is HPTN 052, the first clinical trial to show that treating HIV-infected individuals with antiretroviral therapy (ART) early in their HIV infection resulted in a 96 percent reduction in the risk of sexual transmission of HIV to their uninfected partners. The study was named the “2011 Science Breakthrough of the Year” by Science magazine and resulted in new ART guidance recommendations by the World Health Organization and the Office of the U.S. Global AIDS Coordinator.